At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
Showing 4 of 8

The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.

An indispensable part of the ConsiGma portfolio, the Conductor control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line

A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.

Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
Pets are family – and owners expect premium, transparent and sustainable nutrition. Freeze-drying, powered by GEA technology, helps pet food makers deliver.
Since 2019, GEA has risen from underperformer to DAX member – one of Germany's top 40 listed companies – by fostering entrepreneurship and turning sustainability into a competitive advantage. It reached this milestone in its nearly 145-year history without tailwinds or shortcuts, in a world of compounding crises. This turnaround shows what's possible when purpose and performance align.
This year was a big one for GEA. Can you remember all the milestones and highlights?